Edesa Biotech appoints Peter Weiler as new CFO, succeeding Stephen Lemieux

From GlobeNewswire: 2025-04-04 16:15:00

Edesa Biotech, Inc. appoints Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience in finance and corporate strategy in the biotech and pharma industries. He will succeed Stephen Lemieux, who will step down to pursue other opportunities. Edesa focuses on developing therapeutics for immuno-inflammatory diseases. The company is developing innovative treatments for inflammatory and immune-related diseases, with a clinical pipeline focused on Medical Dermatology and Respiratory areas. Weiler holds an MBA from the University of Western Ontario and has served in various executive roles in the pharmaceutical industry.



Read more at GlobeNewswire: Edesa Biotech Announces Chief Financial Officer Transition